US EditionAbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
Summary by PR Newswire
9 Articles
9 Articles
Farm Talk Newspaper+7 Reposted by 7 other sources
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
NORTH CHICAGO, Ill., June 16, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) did not meet the primary endpoint…
·Parsons, United States
Read Full Article
AbbVie's Phase 3 VERONA Study Of Venetoclax Plus Azacitidine In Myelodysplastic Syndrome Fails
(RTTNews) - AbbVie Inc. (ABBV) Monday said its Phase 3 VERONA study evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) did not meet the primary goal of overall survival (OS).
Coverage Details
Total News Sources9
Leaning Left0Leaning Right0Center7Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
